JLE

Hématologie

MENU

Implication of IDH1 and IDH2 gene mutations in acute myeloid leukemia Volume 17, issue 2, Mars-Avril 2011

Figures

See all figures

Authors
Laboratoire de biologie cellulaire, Hôpital Saint-Louis, Paris, Laboratoire d’hématologie, Centre de biologie-pathologie PM Degand, Lille, EA 3518, Université de Paris 7, Hématologie adulte, Hôpital Saint-Louis, Paris

Among the mutations found in acute myeloid leukemia (AML), those on genes IDH1 and IDH2 (for isocitrate dehydrogenase) are very frequent. According to the latest metaanalyses published, they would be present in approximately 7 % of AML and 14 % of de novo AML. The discovery of these mutations further expands our knowledge about this group of diseases, the mechanisms involved and the evaluation of the risk of relapse. The presence of an IDH1 mutation seems to be particularly poor prognosis among adults under 60 years who have the LAM-CN/ NPM1 + / FLT3wt phenotype and adults under 60 years. The impact of IDH2 mutation is not clear. However, these data could help to refine the 2008 WHO classification by adding new criteria for the evaluation of the benefit of the hematopietic stem cell allograft. This also brings the possibility of new therapeutic approaches.